Equities Analysts Set Expectations for OKUR Q1 Earnings

OnKure Therapeutics (NASDAQ:OKUR) – Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for OnKure Therapeutics in a research report issued to clients and investors on Tuesday, March 18th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($1.41) per share for the quarter, down from their prior forecast of ($1.19). HC Wainwright currently has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.27) EPS, Q4 2025 earnings at ($1.15) EPS and FY2025 earnings at ($5.20) EPS.

Several other analysts have also recently weighed in on OKUR. Leerink Partners began coverage on OnKure Therapeutics in a research report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective on the stock. Leerink Partnrs upgraded OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Finally, Oppenheimer decreased their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a report on Tuesday, March 11th. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $32.33.

OnKure Therapeutics Price Performance

Shares of NASDAQ OKUR opened at $5.05 on Thursday. OnKure Therapeutics has a 1 year low of $4.45 and a 1 year high of $20.00. The stock has a market capitalization of $67.85 million, a PE ratio of -0.41 and a beta of 0.28. The company’s 50-day moving average is $5.44.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings data on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.51).

Institutional Trading of OnKure Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC purchased a new position in OnKure Therapeutics during the fourth quarter valued at $75,000. OMERS ADMINISTRATION Corp bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at $104,000. Walleye Capital LLC purchased a new position in shares of OnKure Therapeutics in the 4th quarter worth about $116,000. Two Sigma Advisers LP bought a new position in OnKure Therapeutics in the 4th quarter worth about $122,000. Finally, Shay Capital LLC purchased a new stake in OnKure Therapeutics during the 4th quarter valued at about $129,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.